Study of Paroxetine and Fluconazole for the Treatment of HIV Associated Neurocognitive Disorder
Summary
The purpose of this study is to see if paroxetine and fluconazole are safe and effective as a treatment for problems with memory, concentration, thinking, and judgment in people who are infected with HIV. Paroxetine is an antidepressant approved by the FDA to treat major depression. Fluconazole is an antifungal medication approved by the FDA to treat fungal infections.
Timeline
- Start
- 2010-11
- Primary completion
- 2016-03
- Completion
- 2016-03
Outcome
Missed primary endpoint
registry analysis (superiority test); Paroxetine and Fluconazole vs Placebo; p = 0.893; Regression, Linear NCT01354314 ↗
registry analysis (superiority test); Paroxetine and Fluconazole vs Placebo; p = 0.673; Regression, Linear NCT01354314 ↗
registry analysis (superiority test); Paroxetine and Fluconazole vs Placebo; p = 0.327; Regression, Linear NCT01354314 ↗
registry analysis (superiority test); Paroxetine and Fluconazole vs Placebo; p = 0.267; Regression, Linear NCT01354314 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fluconazole | Small molecule | 100 mg | Oral |
| Subject | Paroxetine | Small molecule | 20 mg | Oral |